Regulatory compliance – Page 66 – Pharma.Tips

Uncontrolled SOP changes during routine manufacturing – FDA/EMA inspection citation risk

“`html Managing Uncontrolled SOP Changes to Mitigate FDA/EMA Inspection Risks Uncontrolled changes to Standard Operating Procedures (SOPs) during routine manufacturing are a significant risk factor that can lead to regulatory…

Repeated GMP deviations during regulatory inspection – evidence package for inspection defense

A Practical Playbook for Addressing Repeated GMP Deviations During Regulatory Inspections In the highly regulated pharmaceutical environment, repeated Good Manufacturing Practice (GMP) deviations can significantly undermine confidence from regulatory bodies…

Inadequate GMP training during internal audit – root cause analysis inspectors expect

Addressing Inadequate GMP Training During Internal Audits: A Practical Guide Inadequate GMP training during internal audits can lead to significant compliance risks and impacts on manufacturing efficacy, quality systems, and…

Uncontrolled SOP changes during regulatory inspection – how to rebuild GMP maturity

Addressing Uncontrolled SOP Changes During Regulatory Inspections to Enhance GMP Maturity Uncontrolled Standard Operating Procedure (SOP) changes can lead to significant challenges during regulatory inspections, compromising compliance, process integrity, and…

Weak management oversight during regulatory inspection – root cause analysis inspectors expect

Understanding Weak Management Oversight During Regulatory Inspections: A Playbook for Pharmaceutical Professionals In the complex landscape of pharmaceutical manufacturing, weak management oversight can lead to significant regulatory challenges during inspections.…

Inconsistent GMP interpretation during technology transfer – CAPA framework to prevent recurrence

“`html Addressing Discrepancies in GMP Understanding During Technology Transfer: A CAPA Framework In the world of pharmaceutical manufacturing, a common challenge arises during technology transfers: inconsistent interpretations of Good Manufacturing…

Repeated GMP deviations during internal audit – FDA/EMA inspection citation risk

Addressing Recurring GMP Deviations During Internal Audits to Mitigate Inspection Risks Frequent and unresolved Good Manufacturing Practice (GMP) deviations can significantly elevate the risk of receiving citations during FDA, EMA,…

Repeated GMP deviations during internal audit – FDA/EMA inspection citation risk

Managing Repeated GMP Deviations during Internal Audits to Mitigate FDA/EMA Inspection Risks Frequent GMP deviations identified during internal audits pose significant risks for pharmaceutical manufacturing facilities, especially when they could…

Batch documentation gaps during technology transfer – how to rebuild GMP maturity

Addressing Batch Documentation Gaps During Technology Transfer to Enhance GMP Compliance In the lifecycle of pharmaceuticals, technology transfer is a critical process, often fraught with challenges, particularly when it comes…

Poor change control discipline during internal audit – CAPA framework to prevent recurrence

Addressing Poor Change Control Practices in Internal Audits: A Comprehensive CAPA Framework In pharmaceutical manufacturing, poor change control discipline can lead to significant compliance risks, impacting product quality and regulatory…

Batch documentation gaps during scale-up – root cause analysis inspectors expect

Addressing Batch Documentation Gaps During Scale-Up: A Practical Playbook for Pharma Professionals As pharmaceutical companies scale up production, they often encounter significant batch documentation gaps that can jeopardize compliance with…

Weak management oversight during technology transfer – FDA/EMA inspection citation risk

Addressing Weak Management Oversight in Technology Transfer to Mitigate FDA/EMA Inspection Risks In today’s fast-paced pharmaceutical landscape, technology transfers offer unique advantages but also present significant risks, particularly due to…